<!-- Non-Uterine LMS: Content Section -->
<link rel="stylesheet" href="./styles.css" />
<main class="nlmsf-content">
  <!-- Section: Maintenance Therapy After First-Line -->
  <section id="maintenance" class="section-card section-purple">
    <h2 class="section-title">
      Maintenance after First‑Line Treatment for Advanced Soft Tissue Sarcoma
    </h2>
    <p class="section-intro">
      Evidence and perspectives regarding maintenance strategies following initial therapy in advanced soft tissue sarcoma (STS).
    </p>
    <div class="resource">
      <div class="resource-info">
        <h3 class="resource-heading">Peer‑reviewed overview (ScienceDirect)</h3>
        <p class="resource-desc">Explore maintenance options and considerations for advanced STS after first‑line therapy.</p>
        <a class="resource-link" href="https://www.sciencedirect.com/science/article/abs/pii/S1040842825003476" target="_blank" rel="noopener noreferrer">
          Maintenance after first‑line treatment for advanced soft tissue sarcoma – ScienceDirect
        </a>
        <br />
        <a class="resource-link" href="https://www.sciencedirect.com/science/article/pii/S1040842825003476" target="_blank" rel="noopener noreferrer">
          Click here: Maintenance after first‑line treatment for advanced soft tissue sarcoma – ScienceDirect (alternate link)
        </a>
      </div>
    </div>

    <div class="resource">
      <div class="resource-info">
        <h3 class="resource-heading">Maintenance review (PubMed)</h3>
        <p class="resource-desc muted">Review of 8 randomized trials: PFS gains with trabectedin (post doxorubicin/trabectedin) in LMS and anlotinib (post epirubicin/anlotinib) in STS; switch maintenance with regorafenib improved PFS in non‑adipocytic STS; OS benefit seen with doxorubicin/trabectedin in LMS.</p>
        <a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/40975452" target="_blank" rel="noopener noreferrer">
          Maintenance after first‑line treatment for advanced soft tissue sarcoma – PubMed
        </a>
      </div>
    </div>
  </section>

  <!-- Section: Sarcoma NGS Updates 2025 (ASCO) -->
  <section id="ngs-updates-2025" class="section-card section-purple">
    <h2 class="section-title">Sarcoma Next-Generation Sequencing Updates (ASCO 2025)</h2>
    <p class="section-intro">Neal Chawla, MD — key updates on the evolving role of NGS, targeted therapies, cellular therapies, and immunotherapy in sarcoma management.</p>

    <div class="video-embed" style="position:relative;padding-bottom:56.25%;height:0;overflow:hidden;border-radius:12px;box-shadow:0 6px 18px rgba(0,0,0,0.08);">
      <iframe src="https://www.youtube.com/embed/lCKbRPN-WBk" title="Sarcoma NGS Updates 2025"
        frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share"
        allowfullscreen style="position:absolute;top:0;left:0;width:100%;height:100%;border:0;border-radius:12px;"></iframe>
    </div>

    <p class="section-intro" style="margin-top:.75rem;">
      <a href="#" id="open-ngs-summary" class="resource-link">Read summary (opens modal)</a>
    </p>
  </section>

  <!-- Modal: NGS Summary -->
  <div id="ngs-summary-modal" class="nlmsf-modal" role="dialog" aria-modal="true" aria-labelledby="ngs-summary-title" aria-hidden="true">
    <div class="nlmsf-modal__backdrop" data-close="true"></div>
    <div class="nlmsf-modal__dialog" role="document">
      <button class="nlmsf-modal__close" aria-label="Close" data-close="true">×</button>
      <h3 id="ngs-summary-title" class="nlmsf-modal__title">Summary: Sarcoma Next Generation Sequencing Updates in 2025 — Neal Chawla (ASCO 2025)</h3>
      <div class="nlmsf-modal__body">
        <p>This video discusses the evolving role of next-generation sequencing (NGS) in sarcoma management. While NGS testing is becoming more widely adopted, many patients still arrive at specialized centers without prior testing. NGS is unlikely to influence first- or second-line treatments but can identify actionable mutations, such as NTRK fusions, which are treatable with drugs like <strong>larotrectinib</strong>, <strong>entrectinib</strong>, and <strong>repotrectinib</strong>. NGS also helps identify off-label treatment options for rare, treatment-refractory sarcomas, especially when clinical trial participation is not feasible.</p>
        <p>The video highlights the challenges of cellular therapies in solid tumors, including toxicity and limited targets. However, the approval of a <strong>MAGE-A4</strong>–targeting therapy for synovial sarcoma has been a significant milestone, though its applicability is limited by HLA subtype requirements. Other promising molecular targets include <strong>IDH1</strong> mutations in chondrosarcoma (with ongoing phase III trials for <strong>ivosidenib</strong>) and <strong>B7H3</strong>, which is being studied in CAR‑T and antibody‑drug conjugate trials.</p>
        <p>Immunotherapy, particularly immune checkpoint inhibitors, shows limited efficacy as monotherapy but may be more effective when combined with other treatments. The speaker emphasizes the importance of multimodal therapies and multi‑arm studies to address the challenges of treating rare sarcomas. Lastly, the video stresses the need for sarcoma patients to join support groups to build a sense of community and hope.</p>

        <h4>Clinical Trial Highlights</h4>
        <ul>
          <li><strong>Phase III Trial for Ivosidenib in Chondrosarcoma ("CL3")</strong>: Investigating the use of ivosidenib for IDH1‑mutant chondrosarcoma, aiming to evaluate its potential for approval in this rare tumor type.</li>
          <li><strong>B7H3‑Targeted Therapies</strong>: B7H3 is being studied as a molecular target in sarcomas (including osteosarcoma and chondrosarcoma) via two approaches:
            <ul>
              <li>CAR‑T therapy (UCSF)</li>
              <li>Antibody‑drug conjugate trial with promising early results</li>
            </ul>
          </li>
        </ul>

        <h4>Therapies Discussed</h4>
        <ul>
          <li><strong>NGS‑Driven Targeted Therapies</strong>
            <ul>
              <li><strong>NTRK Fusion Treatments</strong>: Larotrectinib, Entrectinib, and Repotrectinib highlighted as effective options when NTRK fusions are identified by NGS.</li>
              <li><strong>Off‑Label Treatments</strong>: NGS reports help identify actionable mutations for off‑label use in rare, treatment‑refractory sarcomas.</li>
            </ul>
          </li>
          <li><strong>Cellular Therapies</strong>
            <ul>
              <li><strong>MAGE‑A4 Targeted Therapy</strong>: Approved for synovial sarcoma; requires specific HLA types (e.g., HLA‑A*02:01), limiting applicability.</li>
            </ul>
          </li>
          <li><strong>Ivosidenib for Chondrosarcoma</strong>
            <ul>
              <li>Used for IDH1‑mutant chondrosarcoma; currently in phase III (CL3) for potential approval.</li>
            </ul>
          </li>
          <li><strong>B7H3‑Targeted Therapies</strong>
            <ul>
              <li>CAR‑T therapy studies</li>
              <li>Antibody‑drug conjugates with encouraging early data (osteosarcoma, chondrosarcoma)</li>
            </ul>
          </li>
          <li><strong>Immunotherapies</strong>
            <ul>
              <li>Checkpoint inhibitors show limited single‑agent activity; combinations (e.g., with immunomodulatory agents) may improve outcomes.</li>
            </ul>
          </li>
          <li><strong>Multimodal Therapies</strong>
            <ul>
              <li>Emphasis on combining standard therapies with novel agents or immunotherapies in multi‑arm studies, especially for rare and difficult‑to‑treat sarcomas.</li>
            </ul>
          </li>
        </ul>

        <h4>Key Practice Updates for Sarcoma in 2025</h4>
        <h5>Next‑Generation Sequencing (NGS) Adoption</h5>
        <ul>
          <li><strong>Increased Use of NGS</strong>: Wider adoption in sarcoma, though some patients still present without prior testing.</li>
          <li><strong>Impact on Treatment</strong>: Unlikely to change 1L/2L therapies; can reveal actionable targets (e.g., NTRK fusions) enabling larotrectinib, entrectinib, or repotrectinib.</li>
          <li><strong>Off‑Label Use</strong>: NGS reports guide off‑label options when clinical trials are unavailable.</li>
        </ul>
        <h5>Targeted Therapies</h5>
        <ul>
          <li><strong>NTRK Fusion Treatments</strong>: Larotrectinib, Entrectinib, Repotrectinib for NTRK fusions.</li>
          <li><strong>Ivosidenib for Chondrosarcoma</strong>: Targets IDH1; in phase III (CL3) for potential approval.</li>
        </ul>
        <h5>Cellular Therapies</h5>
        <ul>
          <li><strong>MAGE‑A4 Targeted Therapy</strong>: Approved for synovial sarcoma; HLA subtype requirements limit breadth of use.</li>
          <li><strong>B7H3‑Targeted Therapies</strong>: CAR‑T and ADC modalities under study.</li>
        </ul>
        <h5>Immunotherapy and Multimodal Approaches</h5>
        <ul>
          <li><strong>Checkpoint Inhibitors</strong>: Limited single‑agent activity; some success in combinations.</li>
          <li><strong>Multimodal Therapies</strong>: Combining standard and novel agents in multi‑arm designs is key for rare sarcomas.</li>
        </ul>
        <h5>Challenges in Clinical Trials</h5>
        <ul>
          <li><strong>Small Patient Populations</strong>: Rare sarcomas challenge conventional trial design.</li>
          <li><strong>Multi‑Arm Studies</strong>: Critical for testing combinations after progression on initial treatments.</li>
        </ul>
        <h5>Patient Support and Advocacy</h5>
        <ul>
          <li>Encourage joining sarcoma‑specific or general support groups to combat isolation and build community, especially for younger patients.</li>
        </ul>

        <h4>Related Management Topics in Sarcoma</h4>
        <ul>
          <li><strong>NGS in Sarcoma</strong>: Identifying actionable mutations (e.g., NTRK fusions) to guide targeted therapies; off‑label exploration when trials are not feasible.</li>
          <li><strong>Targeted Therapies</strong>: Managing mutation‑defined sarcomas (e.g., IDH1 in chondrosarcoma); emerging B7H3‑targeted CAR‑T/ADC therapies.</li>
          <li><strong>Cellular Therapies</strong>: MAGE‑A4 therapy for synovial sarcoma; limitations due to HLA subtypes.</li>
          <li><strong>Immunotherapy Approaches</strong>: Limited single‑agent efficacy; combination strategies.</li>
          <li><strong>Clinical Trial Design</strong>: Small cohorts; need for innovative, multi‑arm designs.</li>
          <li><strong>Supportive Care and Advocacy</strong>: Importance of community and psychosocial support.</li>
        </ul>

        <p class="muted">Note: For alternative viewpoints or deeper dives on specific therapies (e.g., NTRK, MAGE‑A4, B7H3), explore additional expert videos on platforms like VuMedi under the Sarcoma/Oncology categories.</p>
      </div>
    </div>
  </div>

  <script>
    (function(){
      const open = document.getElementById('open-ngs-summary');
      const modal = document.getElementById('ngs-summary-modal');
      if (!open || !modal) return;
      const closeSelectors = '[data-close]';
      function show(){ modal.setAttribute('aria-hidden','false'); modal.classList.add('is-open'); }
      function hide(){ modal.setAttribute('aria-hidden','true'); modal.classList.remove('is-open'); }
      open.addEventListener('click', function(e){ e.preventDefault(); show(); });
      modal.addEventListener('click', function(e){ if (e.target.matches(closeSelectors)) hide(); });
      document.addEventListener('keydown', function(e){ if (e.key === 'Escape' && modal.classList.contains('is-open')) hide(); });
    })();
  </script>

  <!-- Section: Surgical Outcomes -->
  <section id="surgical-outcomes" class="section-card section-blue">
    <h2 class="section-title">Surgical Outcomes: IVC Resection and Graft Replacement</h2>
    <p class="section-intro">Single‑center experience over three decades evaluating safety, durability, and local control following inferior vena cava resection with graft replacement for malignant disease.</p>

    <div class="links-grid">
      <div class="link-card">
        <h3 class="link-title">Early and Late Outcomes (PubMed)</h3>
        <p class="link-desc">IVC resection + graft replacement reported as safe and durable with excellent local control, offering potential long‑term survival in select patients.</p>
        <a class="link-url" href="https://pubmed.ncbi.nlm.nih.gov/40976571/" target="_blank" rel="noopener noreferrer">
          Read the PubMed abstract
        </a>
      </div>
    </div>
  </section>

  <!-- Section: Featured Sarcoma Drug Therapy Chart -->
  <section id="therapy-chart" class="section-card section-blue">
    <h2 class="section-title">Featured Sarcoma Drug Therapy Chart</h2>
    <p class="section-intro">High‑level visual summary accompanying the ScienceDirect article.</p>
    <figure class="image-figure">
      <a href="https://ars.els-cdn.com/content/image/1-s2.0-S1040842825003476-ga1_lrg.jpg" target="_blank" rel="noopener noreferrer">
        <img class="image-responsive" src="https://ars.els-cdn.com/content/image/1-s2.0-S1040842825003476-ga1_lrg.jpg" alt="Featured sarcoma drug therapy chart from ScienceDirect article" />
      </a>
      <figcaption class="image-caption">
        Source: ScienceDirect article “Maintenance after first‑line treatment for advanced soft tissue sarcoma.” Image © respective publisher. Click to view full size.
      </figcaption>
    </figure>
  </section>

  <!-- Section: TNT Phase 2 Study (TVEC + Nivolumab + Trabectedin) -->
  <section id="tnt-study" class="section-card section-teal">
    <h2 class="section-title">Phase 2 TNT Study: Talimogene Laherparepvec (TVEC), Nivolumab, and Trabectedin</h2>
    <p class="section-intro">
      Combination oncolytic immunotherapy and chemotherapy regimen evaluated in advanced sarcomas, including leiomyosarcoma and liposarcoma.
    </p>

    <div class="links-grid">
      <div class="link-card">
        <h3 class="link-title">ASCO Abstract</h3>
        <p class="link-desc">Conference abstract overview of the TNT study (NCT03886311).</p>
        <a class="link-url" href="https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e23560" target="_blank" rel="noopener noreferrer">
          Journal of Clinical Oncology – e23560
        </a>
      </div>

      <div class="link-card">
        <h3 class="link-title">Full Text (PMC)</h3>
        <p class="link-desc">Open‑access paper detailing eligibility, regimen, and outcomes in previously treated STS.</p>
        <a class="link-url" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10206273/" target="_blank" rel="noopener noreferrer">
          Activity of TNT – Frontiers in Oncology (PMC)
        </a>
      </div>

      <div class="link-card">
        <h3 class="link-title">ClinicalTrials.gov</h3>
        <p class="link-desc">Trial registry with protocol information and status updates.</p>
        <a class="link-url" href="https://clinicaltrials.gov/study/NCT03886311" target="_blank" rel="noopener noreferrer">
          NCT03886311 – TNT Study
        </a>
      </div>
    </div>

    <div class="note">
      <strong>Note:</strong> This page is informational only and not a substitute for medical advice. Patients should consult their oncology team for individualized recommendations.
    </div>
  </section>
</main>
